Pre-clinical data of this approach in glioblastoma are lacking, but two phase I trials using this combination therapy are now ongoing: Cabiralizumab, an anti-CSF-1 receptor monoclonal antibody, in combination with nivolumab, is tested in solid cancers, including glioblastoma patients (NCT02526017). Here, CSF1R is linked to glioblastoma.